In this episode of The High Rise, Cy and Emily delve into the latest cannabis news and industry updates. They start by discussing the significant development that the U.S. Department of Health and Human Services (HHS) is conducting an administrative review of cannabis scheduling, with plans to present President Joe Biden with a federal cannabis scheduling decision later this year, as revealed by HHS Secretary Xavier Becerra. Join our hosts as they analyze the potential implications of this review and its impact on the cannabis landscape.
Additionally, Cy and Emily address the recent news of the closure of HERBL, a prominent California cannabis distributor. They examine the reasons behind HERBL's shutdown and use it as a starting point to explore the broader concept of industry shakeouts. Our hosts shed light on how businesses in any industry, including cannabis, undergo natural cycles of restructuring and consolidation. Stick around to end of this episode as they discuss the lessons and implications of industry shakeouts for the cannabis sector.
https://hbr.org/1997/03/strategies-for-surviving-a-shakeout
Related Episodes
E149: From Wheat to Weed: Commerce Clause and Cannabis
Join Emily and Cy as they host Darren Weiss, President of Verano as they discuss the genesis of the historic lawsuit filed against the federal government challenging cannabis prohibition under the Commerce Clause. The lawsuit argues that the federal government's current contradictory stance on...
E146 - High-Rise Live at Benzinga Chicago 2023 with Kris Krane
We are live! Or, were live for that matter. Cannabis pioneer Kris Krane joins the High Rise at Benzinga in Chicago to reflect on his 25+ year career. He discusses pivotal moments like legalization in 2012 and his shift from advocacy to industry. Krane also provides an insider perspective on dynamic...
E137 - It’s time to talk about inflation — THC inflation
In this episode of The High Rise, Cy and Emily dive into the intriguing phenomenon of THC inflation in the cannabis industry. They begin by addressing Organigram's recent earnings call, where CEO Beena Goldenberg highlighted the issue of falsely labeled cannabis products with exaggerated THC l...